For over 20 years, Avi Veidman served in the Israeli intelligence forces, and he used AI to to map the world. In the military he used AI for national defense, and he learned its power.

He then realized that just as AI could map a battlefield, it could map cancer cells in biopsies and pathology slides.

Enter Nucleai, his company that’s using AI to improve the science of “spatial biology,” which can ultimately unlock new treatments and cures…with cancer on their radar.

Avi and I get into how this all works, the staggering potential, and the real-world challenges that need to be overcome. 

Nucleai

https://nucleai.ai

Merck’s $14 million investment in Nucleai:

https://www.businesswire.com/news/home/20240403580481/en/Merck’s-Corporate-Venture-M-Ventures-Arm-Backs-Nucleai-to-Advance-Its-First-in-class-Spatial-AI-Biomarker-in-Active-Clinical-Enrollment

 Stay Connected:

• 🐦 Twitter/X
https://x.com/jeffwilser

• 💼 LinkedIn
https://www.linkedin.com/in/jeffwilser/

• 🖥️ JeffWilser.com
www.JeffWilser.com

🎧 Subscribe to AI-Curious:

• Apple Podcasts
https://podcasts.apple.com/us/podcast/ai-curious-with-jeff-wilser/id1703130308

• Spotify
https://open.spotify.com/show/70a9Xbhu5XQ47YOgVTE44Q?si=c31e2c02d8b64f1b

• YouTube Channel
https://www.youtube.com/@jeffwilser